The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Based in Overland Park, Kansas since 2001, Vince and Associates has become an established industry leader in the successful recruitment and retention of special populations in complex early development clinical trials. The Vince and Associates approach, where study teams are led by highly experienced Principal Investigators intricately involved in all aspects of the clinical trial process, has generated significant industry demand for their services from both large pharmaceutical and biotechnology clients.
“We continue to benefit from the industry shift towards these types of complex studies and joining the Altasciences team will significantly enhance our capabilities while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients,” said Dr. Brad Vince, Founder, President and Medical Director of Vince and Associates. Dr. Vince will continue to act as the CEO and Medical Director.
Altasciences, owned by Kilmer Capital Partners, also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.